Expression of sorcin predicts poor outcome in acute myeloid leukemia

Leukemia Research

Volumn 27, Issue 2, 2003, Pages 125-131

  Tan, Yaohong ^a   Li, Guangyao ^b   Zhao, Chunhua ^a   Wang, Jianxiang ^a   Zhao, Hongguo ^b   Xue, Yanping ^a   Han, Mingzhe ^a   Yang, Chunzheng ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b LIAOCHENG PEOPLE'S HOSPITAL   (China)

Author keywords

AML; cDNA microarray; Multidrug resistance; RT PCR; Sorcin

Indexed keywords

SORCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CALCIUM-BINDING PROTEINS; CHILD; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P-GLYCOPROTEIN; PROGNOSIS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 0037296023     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00083-8     Document Type: Article

References (23)

1. Filipits M., Pohl G., Stranzl T., Suchomel R.W., Scheper R.J., Jager U.et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood. 91:1998;1508.
2. Filipits M., Stranzl T., Pohl G., Heinzl H., Jager U., Geissler K.et al. Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia. 14:2000;68.
3. Ferrao P., Sincock P., Cole S., Ashman L. Intracellular Pgp contributes to functional drug efflux and resistance in acute myeloid leukemia. Leuk. Res. 25:2001;395.
4. Del poeta G., Stasi R., Venditti A., Suppo G., Aronica G., Bruno A.et al. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia. 8:1994;388.
5. Zochbauer S., Gsur A., Brunner R., Kyrle P.A., Lechner K., Pirker R. P-glycoprotein expression as an unfavourable prognostic marker in acute myeloid leukemia. Leukemia. 8:1994;974.
6. List A.F., Spier C.S., Grogan T.M., Johnson C., Roe D.J., Greer J.P.et al. Overexpression of the major vault transporter protein lung-resistance protein products treatment outcome in acute myeloid leukemia. Blood. 87:1996;2464.
7. Leith C.P., Kopecky K.J., Chen I.M., Eijdems L., Slovak M.L., McConnell T.S.et al. Frequency and clinical significance of the expression of the multidrug resistance proteins, MDR1/P-glycoprotein MRP1 and LRP in acute myeloid leukemia: a south-west oncology group study. Blood. 94:1999;1086.
8. Filipits M., Suchomel R.W., Zochbauer S., Brunner R., Lechner K., Pirker R. Multidrug resistance-associated protein (MRP) in acute myeloid leukemia: no impact on treatment outcome. Clin. Cancer Res. 3:1997;1419.
9. Zhongguo Yao Li, Xue Bao. Multidrug resistance in leukemia cell line K562/A02 induced by doxorubicin. Acta Pharmaco Sinica 1995;16:333.
10. Guowai Yi, Xue Yao, Xue Fen Ce. Identification of unknown genes involved in multidrug resistance in K562/A02 cells by cDNA microarray. Acta Acad. Med. Sinica 2001;23:272.
11. Gralnick H.R. Classification of acute leukemia. Ann. Int. Med. 87:1977;740.
12. Rai K.R., Holland J.F., Glidewell O.J., Weinberg V., Brunner K., Obrecht J.P.et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 58:1981;1203.
13. Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield C.D.et al. Report of the National Cancer Institute: sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol. 8:1990;813-819.
14. Ross D.D., Wooten P.J., Tong Y., Cornblatt B., Levy C., Sridhara R.et al. Synergistic reversed of multidrug-resistance phenotype by cyclosporin A and crenophor EL. Blood. 83:1994;1337.
15. Piotr C. One-hour download alkaline capillary transfer for blotting of DNA and RNA. Anal. Biochem. 201:1992;134.
16. Meyers M.B., Biedler J.L. Increased synthesis of a low molecular weight protein in vincristine-resistant cells. Biochem. Biophysic. Res. Commun. 99:1981;228.
17. Meyers MB. Sorcin: a calcium-binding protein overproduced in many multidrug-resistant cells. In: Smith VL, Dedman JR, editors. Stimulus response coupling: the role of intracellular calcium-binding proteins. Boca Raton: CRC Press, 1990. p. 159.
18. Meyers MB. A 22 kDa calcium-binding protein, sorcin, is encoded by amplified genes in multidrug-resistant cells. In: Heizman CW, editor. Novel calcium-binding protein: fundamentals and clinical implications. Heidelberg: Springer, 1991. p. 385.
19. r 22,000 calcium-binding protein (Sorcin) in an adriamycin-resistant myelogenous leukemia cell line. Jpn. J. Cancer Res. 80:1989;469.
20. Lee W.P. Purification, cDNA cloning and expression of human sorcin in vincristine-resistant HOB1 lymphoma cell lines. Arch. Biochem. Biophysic. 325:1996;217.
21. r 22,000 calcium-binding protein (sorcin) associated with multidrug resistance and its detection with monoclonal antibodies. Cancer Res. 48:1988;3173.
22. Van der Bliek A.M., Meyers M.B., Biedler J.L., Hes E., Borst P. A 22-kDa protein (sorcin/V19) encoded by an amplified gene in multidrug-resistant cells, is homologous to the calcium-binding light chain of calpain. EMBO J. 5:1986;3201.
23. Lum B.L., Fisher G.A., Brophy N.A., Yahanda A.M., Adler K.M., Kaubisch S.et al. Clinical trials of modulation of multidrug resistance. Cancer. 72:1993;3502.